Successful treatment of systemic lupus erythematosus with residual disease activity by switching from belimumab to anifrolumab

Affiliations

• ¹ Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
• ² Research Unit for Preventive and Clinical Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
• ³ Department of Rheumatology, Nagasaki Kita Hospital, Nagasaki, Japan.
• ⁴ Nagasaki Medical Hospital of Rheumatology, Nagasaki, Japan.
• ⁵ Department of Rheumatology, National Hospital Organization Nagasaki Medical Center, Omura, Japan.
• ⁶ Department of Rheumatology, Sasebo Chuo Hospital, Sasebo, Japan.